BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, Schobben AF. Paediatric Drug Development and Formulation Design-a European Perspective. AAPS PharmSciTech 2017;18:241-9. [PMID: 27270905 DOI: 10.1208/s12249-016-0558-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Trofimiuk M, Wasilewska K, Winnicka K. How to Modify Drug Release in Paediatric Dosage Forms? Novel Technologies and Modern Approaches with Regard to Children's Population. Int J Mol Sci 2019;20:E3200. [PMID: 31261877 DOI: 10.3390/ijms20133200] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
2 Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. Int J Gen Med 2020;13:1051-66. [PMID: 33204140 DOI: 10.2147/IJGM.S280330] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Saito J, Yoshikawa N, Hanawa T, Ozawa A, Matsumoto T, Harada T, Iwahashi K, Nakamura H, Yamatani A. Stability of Hydrocortisone in Oral Powder Form Compounded for Pediatric Patients in Japan. Pharmaceutics 2021;13:1267. [PMID: 34452228 DOI: 10.3390/pharmaceutics13081267] [Reference Citation Analysis]
4 Feufel MA, Rauwolf G, Meier FC, Karapinar-Çarkit F, Heibges M. Heuristics for designing user-centric drug products: Lessons learned from Human Factors and Ergonomics. Br J Clin Pharmacol 2020;86:1989-99. [PMID: 31663157 DOI: 10.1111/bcp.14134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Yir-Erong B, Bayor MT, Ayensu I, Gbedema SY, Boateng J. The Challenges and Knowledge Gaps in Malaria Therapy: A Stakeholder Approach to Improving Oral Quinine Use in the Treatment of Childhood Malaria in Ghana. J Pharm (Cairo) 2018;2018:1784645. [PMID: 30538884 DOI: 10.1155/2018/1784645] [Reference Citation Analysis]
6 Abruzzo A, Nicoletta FP, Dalena F, Cerchiara T, Luppi B, Bigucci F. Bilayered buccal films as child-appropriate dosage form for systemic administration of propranolol. Int J Pharm 2017;531:257-65. [PMID: 28811117 DOI: 10.1016/j.ijpharm.2017.08.070] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
7 delMoral-Sanchez JM, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Navarro-Ruiz A, Bermejo M. Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics 2020;12:E316. [PMID: 32244848 DOI: 10.3390/pharmaceutics12040316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
8 Preis M, Breitkreutz J. Pediatric Drug Development and Dosage Form Design. AAPS PharmSciTech 2017;18:239-40. [DOI: 10.1208/s12249-016-0705-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
9 Borysowski J, Ehni HJ, Górski A. Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin. Br J Clin Pharmacol 2019;85:2448-9. [PMID: 31410871 DOI: 10.1111/bcp.14068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Thabet Y, Klingmann V, Breitkreutz J. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics. The Journal of Clinical Pharmacology 2018;58:S26-35. [DOI: 10.1002/jcph.1138] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
11 El Zoghbi S, Jannot A, Delacourt C, Abou Taam R, Mamzer M. French pediatricians' views on industry-sponsored clinical trials: Toward stronger research on ethics? Arch Pediatr 2021;28:459-63. [PMID: 34244025 DOI: 10.1016/j.arcped.2021.05.003] [Reference Citation Analysis]
12 Chappell LC, David AL. Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy. PLoS Med 2016;13:e1002161. [PMID: 27802279 DOI: 10.1371/journal.pmed.1002161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Gurjar R, Chan CYS, Curley P, Sharp J, Chiong J, Rannard S, Siccardi M, Owen A. Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. Mol Pharm 2018;15:4835-42. [PMID: 30350641 DOI: 10.1021/acs.molpharmaceut.8b00482] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
14 Freerks L, Sommerfeldt J, Löper PC, Klein S. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound – A promising starting point for future PUMA applications. European Journal of Pharmaceutics and Biopharmaceutics 2020;156:11-9. [DOI: 10.1016/j.ejpb.2020.08.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Korth-Bradley JM. The Path to Perfect Pediatric Posology - Drug Development in Pediatrics. J Clin Pharmacol 2018;58 Suppl 10:S48-57. [PMID: 30248197 DOI: 10.1002/jcph.1081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Strickley RG. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007. Journal of Pharmaceutical Sciences 2019;108:1335-65. [DOI: 10.1016/j.xphs.2018.11.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
17 Govender R, Abrahmsén-alami S, Larsson A, Folestad S. Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics 2020;149:58-76. [DOI: 10.1016/j.ejpb.2020.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
18 Bracken L, McDonough E, Ashleigh S, Wilson F, Shakeshaft J, Ohia U, Mistry P, Jones H, Kanji N, Liu F, Peak M. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)). BMJ Open 2020;10:e036508. [PMID: 33039988 DOI: 10.1136/bmjopen-2019-036508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Siafaka P, Ipekci E, Caglar EŞ, Ustundag Okur N, Buyukkayhan D. Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives. Medeni Med J 2021;36:152-62. [PMID: 34239768 DOI: 10.5222/MMJ.2021.78476] [Reference Citation Analysis]
20 Saito J, Hanawa T, Matsumoto T, Yoshikawa N, Harada T, Iwahashi K, Nakamura H, Yamatani A. Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan. J Pharm Health Care Sci 2021;7:31. [PMID: 34465373 DOI: 10.1186/s40780-021-00214-x] [Reference Citation Analysis]
21 Kozarewicz P, Loftsson T. Novel excipients - Regulatory challenges and perspectives - The EU insight. Int J Pharm 2018;546:176-9. [PMID: 29792985 DOI: 10.1016/j.ijpharm.2018.05.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mancini M, Shafai G, Thaler E, Donovan JM, Finkel RS. Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent. J Clin Pharm Ther 2021. [PMID: 34263472 DOI: 10.1111/jcpt.13478] [Reference Citation Analysis]
23 Okubo K, Uchida E, Terahara T, Akiyama K, Kobayashi S, Tanaka Y. Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinitis. Allergology International 2018;67:371-9. [DOI: 10.1016/j.alit.2017.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Thabet Y, Slavkova M, Breitkreutz J. 10 years EU regulation of pediatric medicines – impact on cardiovascular drug formulations. Expert Opinion on Drug Delivery 2017;15:261-70. [DOI: 10.1080/17425247.2018.1420054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shawahna R, Zyoud A, Haj-Yahia A, Taya R. Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System. AAPS PharmSciTech 2021;22:84. [PMID: 33649887 DOI: 10.1208/s12249-021-01958-3] [Reference Citation Analysis]
26 Castro JCDSXE, Botelho SF, Machado TRL, Martins MAP, Vieira LB, Reis AMM. Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups. Einstein (Sao Paulo) 2018;16:eAO4354. [PMID: 30427486 DOI: 10.31744/einstein_journal/2018AO4354] [Reference Citation Analysis]
27 Karavasili C, Gkaragkounis A, Fatouros DG. Patent landscape of pediatric-friendly oral dosage forms and administration devices. Expert Opin Ther Pat 2021;31:663-86. [PMID: 33605825 DOI: 10.1080/13543776.2021.1893691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pechová V, Gajdziok J, Muselík J, Vetchý D. Development of Orodispersible Films Containing Benzydamine Hydrochloride Using a Modified Solvent Casting Method. AAPS PharmSciTech 2018;19:2509-18. [DOI: 10.1208/s12249-018-1088-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]